- Home
- UGRO vs TNXP Comparison
UGRO vs TNXP Comparison
Compare UGRO & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UGRO
- TNXP
- Stock Information
- Founded
- UGRO 2014
- TNXP 2007
- Country
- UGRO United States
- TNXP United States
- Employees
- UGRO N/A
- TNXP N/A
- Industry
- UGRO Industrial Specialties
- TNXP Biotechnology: Pharmaceutical Preparations
- Sector
- UGRO Consumer Discretionary
- TNXP Health Care
- Exchange
- UGRO Nasdaq
- TNXP Nasdaq
- Market Cap
- UGRO 18.0M
- TNXP 19.5M
- IPO Year
- UGRO N/A
- TNXP N/A
- Fundamental
- Price
- UGRO $1.07
- TNXP $0.61
- Analyst Decision
- UGRO Strong Buy
- TNXP Strong Buy
- Analyst Count
- UGRO 2
- TNXP 2
- Target Price
- UGRO $5.63
- TNXP $53.50
- AVG Volume (30 Days)
- UGRO 55.7K
- TNXP 202.6M
- Earning Date
- UGRO 12-27-2024
- TNXP 11-12-2024
- Dividend Yield
- UGRO N/A
- TNXP N/A
- EPS Growth
- UGRO N/A
- TNXP N/A
- EPS
- UGRO N/A
- TNXP N/A
- Revenue
- UGRO $70,320,066.00
- TNXP $11,291,000.00
- Revenue This Year
- UGRO $14.76
- TNXP $62.53
- Revenue Next Year
- UGRO $21.29
- TNXP $26.17
- P/E Ratio
- UGRO N/A
- TNXP N/A
- Revenue Growth
- UGRO 12.08
- TNXP 183.05
- 52 Week Low
- UGRO $0.93
- TNXP $0.12
- 52 Week High
- UGRO $2.84
- TNXP $14.08
- Technical
- Relative Strength Index (RSI)
- UGRO 33.37
- TNXP 75.02
- Support Level
- UGRO $1.17
- TNXP $0.32
- Resistance Level
- UGRO $1.19
- TNXP $0.72
- Average True Range (ATR)
- UGRO 0.11
- TNXP 0.15
- MACD
- UGRO -0.02
- TNXP 0.04
- Stochastic Oscillator
- UGRO 24.78
- TNXP 39.61
About UGRO urban-gro Inc.
Urban-gro Inc is an integrated professional services and construction design-build firm. Its business focuses predominantly on providing fee-based knowledge-based services as well as the value-added reselling of equipment. The company offers value-added architectural, engineering, systems procurement and integration, and construction design-build solutions to customers operating in the controlled environment agriculture (CEA) and industrial and other commercial (Commercial) sectors. It derives revenue predominately from the sale of equipment systems, services, construction design-build, and other various immaterial contracts with customers.
About TNXP Tonix Pharmaceuticals Holding Corp.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.